INSM Insmed Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INSM

Price (delayed)

$118.34

Market cap

$25.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.1

Enterprise value

$26.04B

?
Relative Growth: Rel. Growth: 90
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 30

Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company's lead candidate ARIKACE, is engineered to ...

Highlights
INSM's revenue has surged by 186% year-on-year and by 39% since the previous quarter
The company's gross profit rose by 42% QoQ
The equity is down by 39% YoY but it is up by 7% from the previous quarter
The company's quick ratio fell by 49% YoY and by 19% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.insmed.com
Peers: SRPT GILD ARRY NVS

Key stats

What are the main financial stats of INSM

INSM stock price

How has the Insmed stock price performed over time
Intraday
-2.05%
1 week
-3.46%
1 month
-5.91%
1 year
-18.6%
YTD
-32%
QTD
10.99%

Financial performance

How have Insmed's revenue and profit performed over time
Revenue
$1.14B
Gross profit
$949.42M
Operating income
-$987.34M
Net income
-$875.31M
Gross margin
83.5%
Net margin
-76.9%
INSM's revenue has surged by 186% year-on-year and by 39% since the previous quarter
The net margin has soared by 70% YoY and by 47% from the previous quarter
Insmed's operating margin has soared by 63% YoY and by 38% from the previous quarter
The company's gross profit rose by 42% QoQ

Price vs fundamentals

How does INSM's price correlate with its fundamentals

Growth

What is Insmed's growth rate over time

Valuation

What is Insmed stock price valuation
P/E
N/A
P/B
33.86
P/S
22.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.89
The EPS has grown by 29% since the previous quarter and by 28% year-on-year
The equity is down by 39% YoY but it is up by 7% from the previous quarter
The price to book (P/B) is 15% lower than the last 4 quarters average of 40.7
INSM's revenue has surged by 186% year-on-year and by 39% since the previous quarter
INSM's price to sales (P/S) is 51% lower than its last 4 quarters average of 47.2 and 10% lower than its 5-year quarterly average of 25.6

Efficiency

How efficient is Insmed business performance
The ROS has soared by 71% year-on-year and by 48% since the previous quarter
INSM's ROE is up by 43% YoY and by 14% from the previous quarter
The ROIC has grown by 30% since the previous quarter and by 3.9% year-on-year
The company's return on assets rose by 23% QoQ and by 20% YoY

Dividends

What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INSM.

Financial health

How did Insmed financials performed over time
INSM's total assets is 56% higher than its total liabilities
The company's quick ratio fell by 49% YoY and by 19% QoQ
The current ratio has contracted by 44% YoY and by 17% from the previous quarter
The debt is 2.3% less than the equity
The debt to equity has soared by 66% YoY but it is down by 7% from the previous quarter
The equity is down by 39% YoY but it is up by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.